drugset / Trial / NCT04064983

Individual Patient Expanded Access IND to Treat Polyneuropathy

NCT04064983 ↗

Expanded access No longer available Hope Biosciences Research Foundation

Summary

This Individual Patient Expanded Access IND has been created as requested by an 58-year-old man who suffers from Polyneuropathy due to Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin abnormalities (POEMS) Syndrome. The patient will receive 8 infusions of 200 million cells every four weeks during a 28-week period to relieve the symptoms of Polyneuropathy arising due to POEMS.

Timeline

Start
—
Primary completion
—
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject HB-adMSCs Cell therapy 2e+08 cells Intravenous

Indications